Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 2, 2005, Pages 161-168

  Beregszaszi, Marta ^a   Dollfus, Catherine ^b   Levine, Martine ^c   Faye, Albert ^c   Deghmoun, Samia ^a   Bellal, Nassima ^d   Houang, Muriel ^b   Chevenne, Didier ^c   Hankard, Régis ^c   Bresson, Jean Louis ^d   Blanche, Stéphane ^d   Levy Marchal, Claire ^a,c  

^a INSERM   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Children; HIV; Insulin resistance; Lipodystrophy; Puberty; Treatment

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; INSULIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

ARTICLE; BLOOD TRANSFUSION; BODY MASS; CLINICAL TRIAL; DISEASE DURATION; ETHNOLOGY; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPODYSTROPHY; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBERTY; RISK FACTOR; SCHOOL CHILD; SEXUAL MATURATION; SKINFOLD THICKNESS; STATISTICAL ANALYSIS; THYROTROPIN BLOOD LEVEL; VERTICAL TRANSMISSION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 25844487693     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000178930.93033.f2     Document Type: Article

References (20)

1. Amaya RA, Kozinetz CA, McMeans A, et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:405-410.
2. + lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001;27:30-34.
3. Bockhorst JL, Ksseiry I, Toye M, et al. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J. 2003;22:463-465.
4. Brambilla P, Bricalli D, Sala N, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of Iipodystrophy. AIDS. 2001;15:2415-2422.
5. European Paediatric Lipdystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443-1451.
6. Jaquet D, Levine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS. 2000;14:2123-2128.
7. Lainka E, Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics. 2002;110:e56.
8. Melvin AJ, Lennon S, Mohan KM, et al. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses. 2001;17:1117-1123.
9. Taylor P, Worrell C, Steinberg SM, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics. 2004;114: e235-e242.
10. Vigano A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr. 2003;32:482-489.
11. Wedekind CA, Pugatch D. Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy. 2001;21:861-866.
12. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov. 2003;2:624-634.
13. Rolland-Cachera MF, Cole TJ, Sempe M, et al. Body mass index variations: centiles from birth to 87 years. Eur J Clin Nutr. 1991;45:13-21.
14. Schwenk A, Beisenherz A, Kremer G, et al. Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment. Am J Clin Nutr. 1999;70:867-873.
15. Rolland-Cachera MF, Bellisle F, Deheeger M, et al. Influence of body fat distribution during childhood on body fat distribution in adulthood: a two-decade follow-up study. Int J Obes. 1990;14:473-481.
16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
17. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43(RR-12):1-10.
18. Christensen B, Glueck C, Kwiterovich P, et al. Plasma cholesterol and triglyceride distributions in 13,665 children and adolescents: the Prevalence Study of the Lipid Research Clinics Program. Pediatr Res. 1980;14:194-202.
19. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-735.
20. Moran A, Jacobs DR, Steinberger J, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes. 1999;48:2039-2044.